1
1
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
https://vocero.uach.mx/index.php/tecnociencia
ISSN-e: 2683-3360
Artículo Científico
Inhibitory effects of Buddleja scordioides (salvilla)
leaves on digestive enzymes and carbohydrate
absorption in vivo
Efectos inhibidores de las hojas de Buddleja scordioides (salvilla) sobre
las enzimas digestivas y la absorción de carbohidratos in vivo
*Correspondencia: nrocha@itdurango.edu.mx (Nuria E. Rocha-Guzmán), clau140382@hotmail.com (Claudia I. Gamboa-
Gómez2)
DOI: https://doi.org/10.54167/tch.v17i2.1221
Recibido:: 31 de mayo de 2023; Aceptado: 15 de agosto de 2023
Publicado por la Universidad Autónoma de Chihuahua, a través de la Dirección de Investigación y Posgrado
Abstract
The effects of Buddleja scordioides (BsLI) leaf infusions on digestive enzymes and carbohydrate
absorption were evaluated. The BsLI yield was 21.64 %. In addition, a chemical characterization was
carried out identifying hydroxybenzoic acids, hydroxycinnamic acids, flavonols, flavanones and
flavones. In vitro studies were performed to determine the inhibitory action of BsLI on lipase, α-
amylase, and α-glucosidase. Then, in rats, oral starch tolerance tests (OSTT) were carried out using
BsLI at a dose of 9.5 mg/kg body weight. Results showed moderate inhibition of lipase and α-
glucosidase, but greater inhibition of α-amylase compared to positive controls. During the OSTT
trial, the group receiving BsLI showed a significant reduction in glucose levels compared to the
negative control group. Bioactive compounds, such as naringenin, luteolin, quercetin, and coumaric
acid, were identified after BsLI administration. Furthermore, the consumption of BsLI was safe and
showed antioxidant activity like Trolox. In conclusion, BsLI may have an enhanced effect on glucose
metabolism by inhibiting carbohydrate absorption.
Laura J. Barragan-Zuñiga2, Luis E. Simental-Mendía2, Mayra Denise Herrera3, Rubén F.
González-Laredo1, J. Alberto Gallegos-Infante1, José Salas-Pacheco4, Martha R. Moreno-
Jiménez1, Nuria E. Rocha-Guzmán1*, Claudia I. Gamboa-Gómez2 *
1 Instituto Tecnológico de Durango. Blvd. Felipe Pescador 1830, Nueva Vizcaya, 34080 Durango, Dgo.
2 Unidad de Investigación Biomédica del Instituto Mexicano del Seguro Social. Predio Canoas, 34077
Durango, Durango.
3 Instituto Nacional de Investigaciones Forestales Agrícolas y Pecuarias. Campo Experimental Zacatecas
Kilómetro 24.5, Zacatecas - Fresnillo, Zacatecas.
4 Instituto de Investigación Científica, Universidad Juárez del Estado de Durango. Universidad y Fanny
Anitua SN, Zona Centro, 34000 Durango, Durango.
2
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Keywords: medicinal plant, carbohydrate absorption, antioxidant, Buddleja scordioides
Resumen
Se evaluaron los efectos de las infusiones de hojas de Buddleja scordioides (BsLI) sobre enzimas
digestivas y la absorción de carbohidratos. El rendimiento de BsLI fue del 21.64 %. Además, se
caracterizaron componentes químicos: ácidos hidroxibenzoicos, ácidos hidroxicinámicos,
flavonoles, flavanonas y flavonas. En estudios in vitro, se examinó cómo BsLI inhibe la lipasa, α-
amilasa y α-glucosidasa. Luego, en ratas, se probó su efecto en la tolerancia oral al almidón (OSTT)
a dosis de 9.5 mg/kg de peso corporal. Resultados indicaron moderada inhibición de lipasa y α-
glucosidasa, y mayor inhibición de α-amilasa comparado con controles. Durante la OSTT, el grupo
con BsLI tuvo menor glucosa que el control negativo. Tras administrar BsLI, se detectaron
compuestos bioactivos: naringenina, luteolina, quercetina y ácido cumárico. Además, BsLI fue
seguro, con actividad antioxidante similar al Trolox. En conclusión, BsLI puede tener un efecto
beneficioso sobre el metabolismo de la glucosa al inhibir la absorción de carbohidratos.
Palabras clave: planta medicinal, absorción de carbohidratos, antioxidante, Buddleja scordioides
1. Introduction
The western lifestyle is characterized by a lack of physical activity and hypercaloric diets. These
are the main contributing factors to the development of metabolic diseases such as obesity and type
2 diabetes (Kopp, 2019). A therapeutic target of these diseases is the inhibition of digestive enzymes
such as pancreatic lipase, α-amylase, and α-glucosidase (Patil et al., 2015; Irondi et al., 2018).
These digestive enzymes break down dietary lipids and carbohydrates to produce absorbable
molecules such as free fatty acids and monosaccharides. Thus, the inhibition of these enzymes
reduces the amounts of calories absorbed into the body and postprandial glucose (Awosika et al.,
2019). Pharmacological drugs such as acarbose and orlistat inhibit digestive enzymes involved in
glucose and lipid metabolism. However, they often exhibit side effects ranging from diarrhea to
hepatotoxicity, which limit their use in the clinical setting (Lunagariya et al., 2014). In this regard,
previous studies reported that different bioactive compounds (e.g. polyphenols) present in medicinal
plants inhibit one or more digestive enzymes with lesser adverse effects than the drugs
(Ardeshirlarijani et al., 2019; Gutiérrez-Grijalva et al., 2019).
Several species of Buddleja spp. are recognized to treat ills related to inflammatory processes (Estrada-
Zúñiga et al., 2019). Additionally, Hwang et al., (2009) found that B. officinalis improves
hyperglycemia, endothelium-dependent vascular relaxation, and inflammation in a diabetic
atherosclerotic mouse model. Previous experimental studies have revealed the diverse biological
activities of Buddleja scordioides, commonly known as salvilla. In a study published in 2002,
VanderJagt et al. demonstrated the anti-inflammatory potential of salvilla. Their findings indicated
that the plant extract could effectively inhibit the production of inflammatory cytokines in rats,
suggesting its potential for reducing inflammation in conditions like arthritis, asthma, and
inflammatory bowel disease. Rocha-Guzmán et al. conducted research in 2018 to explore the
gastroprotective effects of salvilla. Their study revealed that the extract provided protective benefits
to the stomach lining. Furthermore, a study by Villegas-Novoa et al. in 2020 reported the antioxidant
3
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
effects of Buddleja scordioides extract in rats. The research demonstrated that the plant's extract
exhibited antioxidant properties, protecting cells from damage caused by free radicals. These
observed benefits have been associated with the bioactive compounds found of this herbal product,
which include iridoids, phenylpropanoids, sesquiterpenes, saponins, verbascosides, and flavonoids.
These compounds have shown a variety of beneficial effects, including antioxidant and anti-
inflammatory properties, as reported by Santos-Cruz et al. (2012) and Gutiérrez-Rebolledo et al.
(2019).
However, to the best of our knowledge, there is no evidence investigating the impact of B. scordioides
on digestive enzymes and carbohydrate absorption in vivo. Therefore, the aim of this study was to
evaluate the in vitro inhibitory effects of BsLI on digestive enzymes and carbohydrate absorption in
vivo. In addition, the oral BsLI-bioactive-compounds absorption (OBCA), antioxidant activity, and
safety of this medicinal plant were investigated.
2. Materials and methods
2.1 Materials
Samples of Buddleja scordioides Kunth (salvilla) were collected at Ignacio Ramirez road in
Durango, México (coordinates 24°30´17.41” N, length 104°4´51.23” W, elevation 2030 m average).
The botanist Dr. Socorro González-Elizondo taxonomically identified leaves and the voucher
specimens (47538) were deposited at the Herbarium of the Centro Interdisciplinario de Investigación
para el Desarrollo Integral Regional del Instituto Politécnico Nacional, Unidad Durango, México.
The leaves were air dried in the shade at 25 C followed by milling to a particle size of 0.7-1.0 mm.
2.2 Preparation of Buddleja scordioides leaves infusions (BsLI)
The infusion concentration was commonly used by the general population (1 % m/v). The dried
leaves sample (2 g) was added to 200 mL boiling water and kept stirring for 10 min. Infusions were
obtained by subsequent filtration and lyophilized (FreeZone 18 Liter Console Freeze Dry System,
Kansas USA). Samples were stored in amber vessels until use.
2.3 Yields of extractable solids
Infusion yield was determined as follows:
Yield (%)=[(Lyophilized infusion (g))/(Dried plant material (g)) ]100 Eq (1)
Results are reported as means of two independent infusion preparation.
4
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
2.4 Chemical characterization of BsL
Sample analysis was carried out with an Acquity UPLC system (Waters Corp., Milford)
coupled with a tandem Xevo TQ-S triple quadrupole mass spectrometer (Waters Corp., Wexford).
The LC system consisted of a sample manager (5 C) and a quaternary solvent manager. The column
used to determine the phenolic profile was an Acquity UPLC BEH C8, 1.7 µm, 2.1 mm x 100 mm
(Waters Corp., Wexford), operated at 30 C. The mobile phase included two solvents: acidified Milli
Q water with 7.5 mM formic acid (Solvent A) and acetonitrile LC-MS (Solvent B): Initial 5 % B, 0.8
min isocratic to 5 % B, 1.2 min gradient to 10 % B; 1.9 min isocratic 10 % B; 2.4 min gradient to 15 %
B; 3.7 min isocratic 15 % B; 4.0 min gradient to 21 % B; 5.2 min isocratic 21 % B; 5.7 min gradient to
reach 27 % B; 8.0 min gradient to reach 50 % B; 9.0 (linear gradient) for column washing 100 % B;
subsequent at 11.5 min linear gradient 5 % B since 13.5 min for column stabilization at a flow rate of
250 µL/min. Electron spray ionization (ESI) in negative mode was as follows: capillary voltage 2.5
kV, desolvation temperature 300 C, source temperature 150 C, desolvation gas flow 500 L/h, and
cone gas flow 150 L/h, collision gas flow was 0.14 mL/min, MS mode collision energy 5.0 and MS/MS
mode collision energy 20.0. For identification and quantification of the phenolic profile, a mixture of
standards (20 ng/µL) was used for monitoring retention times, m/z values, and MS/MS transitions.
Samples and standards were monitoring at multiple modes. The UPLC and Tandem Xevo TQ-S
triple quadrupole mass spectrometer control and data processing was using MassLynx v. 4.1
Software (Waters Corp.).
2.5 Inhibitory effects of BsLI on digestive enzymes
2.5.1 Pancreatic lipase inhibition assay
The assay was performed following the methodology reported by McDougall et al. (2009),
with some modifications. In brief, 150 μL of a solution (10 mg/mL) of porcine pancreatic lipase type
II (Sigma- Aldrich, Cat. No. L3126) was mixed with BsLI (at 10, 50, 100, 200, 400, 600, 800, and 1000
µg/µL), 400 μL of Tris buffer (100 mM, pH 8.2), 400 µL of p-nitrophenyl laurate (SIGMA Co., St.
Louis, USA), and substrate solution (0.08 % w/v dissolved in 5 mM sodium acetate at pH 5.0
containing 1 % Triton X-100). Samples were incubated at 37 °C for 2 h and centrifuged at 16,000 RPM,
for 3 min. Finally, the supernatant was read at 400 nm using a microplate reader (MultiScan Go,
Thermo Scientific, USA). The positive control was Orlistat (Redustat® Laboratorios Liomont S.A. DE
C.V.).
The lipase inhibitory activity was expressed as a percentage of inhibition:
Inhibition %=100S_0-S_1)/S_(0) Eq (2)
Where S_0 is the absorbance of the blank and S_1 is the absorbance of BsLI.
Additionally, BsLI concentration that provided 50 % inhibition (IC50) was calculated by plotting the
inhibition percentage versus the log concentration curve (Coruh et al., 2007).
5
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
2.5.2 -Amylase inhibition assay
The assay was performed following the methodology reported by Tamil et al. (2010) with
several modifications. Substrate solution was performed using starch (4 %), CaCl2 0.01 M, and
distilled water (5 mL) for 5 min at 96 °C. The BsLI (at 10, 50, 100, 200, 400, 600, 800, and 1000 µg/µL)
were incubated for 1 h at 37 °C with 100 µL of porcine pancreas α-amylase solution (2.5 mU/µL in
sodium phosphate buffer (0.02 M, pH 6.9) and sodium chloride (6 mM)) (SIGMA Co., St. Louis, USA).
Afterward, to stop the reaction, NaOH (4 mL, 0.1 M) was added, and a centrifugation step was
performed (700 xg for 5 min). Glucose concentration in the supernatant was determined using an
enzymatic kit (Biosystems Instruments Reagents, Barcelona, Spain). Acarbose (Laboratorios
Alpharma, CDMX, México) was used as a positive control. Results were expressed as inhibition
percentage (equation 2) and IC50.
2.5.3 -Glycosidase inhibition assessment
The assay was performed following the methodology reported by Apostolidis et al. (2007).
Sample of BsLI (25 μL at 20, 40, 60, 80, and 100 µg/µL), 100 µL of glucosidase enzyme (SIGMA Co.,
St. Louis, USA) (0.19 mU/µL), and 50 μL of phosphate buffer (0.1 M, pH 6.9) were mixed and
incubated for 10 min at 37 °C. Then, 25 µL of p-nitrophenyl-α-D-glucopyranoside solution (5 mM/L
prepared in a 0.1 M/L of citratephosphate buffer, pH 7) (SIGMA Co., St. Louis, USA) was added
and incubated 30 min at 37 °C. The reaction was stopped by adding 1 mL of a 0.05 mol/L NaOH
solution. Samples were read at 410 nm with the Synergy HT Microplate Reader (Biotek Instruments,
Winooski, Vermont, USA.). Acarbose (Laboratorios Alpharma, CDMX, México) was used as a
positive control. Results were expressed as inhibition percentage (equation 2) and IC50.
2.6 Antioxidant activity of BsLI in vitro.
2.6.1 Determination of radical scavenging activity using the ABTS assay
The ABTS assay was performed following the methodology reported by Re et al. (1999). In
brief, potassium persulfate (2.5 mM) was mixed and incubated in dark for 16 h at 25±1 °C with ABTS
(7 mM) to produce the radical cations. The BsLI (2.5 µL at 10, 50, 150, 200, 250, 300, 350, and 400
μg/mL) were added to the ABTS solution (200 µL). Trolox was the positive control. Afterward, the
absorbance was recorded, and the results were expressed as the inhibition percentage (equation 2)
and as IC50.
2.6.2 Radical scavenging assay: Diphenylpicrylhydrazyl (DPPH)
The DPPH assay was performed following the methodology reported by Brand-Williams et
al. (1995). One mL of the stable free radical DPPH solution (20 mg/L) was mixed with 200 µL of BsLI
(at concentration of 10, 50, 100, 200, 400, 500, 600, 700 and 800 μg/mL). Samples were incubated for
30 min in dark at room temperature (26 C).The absorbance was registred at 515 nm. Trolox was the
positive control. The results were expressed as the inhibition percentage (equation 2) and as IC50.
6
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
2.7 Effect of BsLI on carbohydrate absorption in vivo.
2.7.1 Animals/ethics approval
Animal experiments were carried out in accordance with the Mexican guidelines
(NOM-062-ZOO-1999) and the National Institutes of Health (2002) recommendations for research
with animals.
Animals used in the experiments were male Wistar rats (ten weeks old, n = 8, 180 ± 20 g of body
weight) and male CD-1 mice (eight weeks old, n=28, 25 ± 5 g of body weight), as well as non-pregnant
female CD-1 mice (eight weeks old, n=6, 25 ± 5 g of body weight). All animals were obtained from
the same source, Universidad Nacional Autónoma de México (UNAM), campus Juriquilla,
Querétaro, México.
They were housed in a controlled environment with a 1212 h lightdark cycle and maintained at a
temperature of 27 ± 1 C. Water and food (Rodent Lab Chow 5001, Purin, Québec, Canada) were
provided ad libitum for all the animals during the experiments.
2.7.2 Oral starch tolerance test (OSTT)
Effects of BsLI on carbohydrate absorption were assessed with an oral starch tolerance test
(OSTT). Starch was the negative control, whereas the positive control was acarbose.
In fasting conditions, male Wistar rats (ten weeks old, n = 8, 180 ± 20 g of body weight) were given a
starch load at a dose of 3 g/kg of body weight (equivalent to 519.26 mg contained in an infusion cup
of 240 mL consumed by an adult of 70 kg by a meal). Additionally, 5.12 mg/Kg of body weight of
acarbose was used as a positive control (equivalent to 50 mg by a meal in humans). Blood glucose
levels were determined in blood samples collected from the tail vein using a glucometer (Stat Strip®
Glucose, Nova Biomedical, Waltham, MA, US) at 0, 30, 60, and 120 min. The variations in serum
glucose onset time, peak, and AUC were considered to the determination of the relative rate of
carbohydrate digestion and absorption.
The human dose extrapolation (HED) to the animal was estimated according to the following
formula:
HED = animal dose (mg/kg) [animal weight (kg/human weight in kg)] 0.33
Reagan-Shaw et al. (2008)
Eq (3)
2.8 Oral absorption assay of BsLI bioactive compounds (OABC)
The oral absorption assay was conducted on male CD-1 mice (eight weeks old, n=28, 25 ± 5
g of body weight). The mice were placed in metabolic cages and fasted for 12 hours before the
experiment. Treatments (n=4 per time point) were administered through gavage at a dose of 2500
mg/kg of body weight to the intervention groups at various time intervals (0, 0.5, 2, 4, 8, 12, and 24
hours). The negative control group received water as the vehicle. After each treatment, the mice were
anesthetized and euthanized by cardiac puncture. Serum was separated from the blood and
immediately frozen at -80 C for later analysis.
7
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
The analysis of the serum samples involved adding 100 µL of serum to a mixture containing 37 μL
of water with 200 µg/µL of ascorbic acid and 1 µg/µL of EDTA. The mixture was then centrifuged at
14000 g for 10 minutes, and 250 μL of ethyl acetate was added for liquid-liquid micro-extraction. The
suspension was mixed using a vortex for 1 minute. The collected volumes were dried using a
vacuum centrifugal console, reconstituted in methanol (200 µL), and filtered through 0.45 µm
syringe filters. The identification and quantification of BsLI bioactive compounds present in mouse
serum were performed following the methodology previously described in section 2.4 on "the
chemical characterization of BsLI".
2.9 Toxicity assessment of BsLI
2.9.1 Acute toxicity
The acute toxicity assay was carried out on non-pregnant female CD-1 mice (eight weeks
old, n=6, 25 ± 5 g of body weight) (Universidad Nacional Autónoma de México, campus Juriquilla,
Querétaro, México). The guidelines of the Organization for Economic Cooperation and Development
for testing of chemicals 420 (OECD, 2001) were followed. The Mice were divided into two groups of
three animals each. A single dose of BsLI (5000 mg/kg of body weight) was administered via gavage
(in distilled water). Mice were observed for signs of possible toxicity (convulsions, tremors, lethargy,
salivation, diarrhea, sleepiness, and coma) every hour for the first four hours, and then the animals
were fed. Thereafter, mice were monitored for any signs of toxicity (changes in the eyes, skin, fur,
mucous membranes, and the respiratory, circulatory, and autonomic nervous and central nervous
systems) and mortality for 14 days. Measurements of body weight and food and water intake were
performed daily. On the last day, animals were sacrificed under deep ether anesthesia and the
median lethal dose (LD50) values were estimated. Vital organs such as the heart, kidney, liver,
spleen, and lung were isolated and weighted to assess histopathological changes. The organs were
fixed in 10 % buffered neutral formalin, embedded in paraffin wax, cut (5 µm) on glass slides, and
stained with hematoxylin and eosin. The slides were examined under a light microscope.
2.9.2 Sub-chronic toxicity
For the sub-chronic toxicity assessment, both female and male mice aged eight weeks and
weighing 25 ± 5 g of body weight (UNAM, Campus Juriquilla, Querétaro, México) were used.
The assay was performed according to the methodology described by the Organization for Economic
Co-operation and Development-407 (OECD, 2008). Animals were divided into four groups of 10 each
(five males and five females). The control group received distilled water (vehicle), while the three
intervention groups received BsLI by gavage at doses of 250, 750, and 2500 mg/kg of body weight,
respectively, for 28 days. Mice were observed for signs of abnormalities during the treatment period.
Measurements of body weight and food and water intake were performed daily.
Before sacrifice, urine was collected and analyzed using urinalysis strips (Bio-Uridiag-A10) for the
measurement of leucocytes, nitrite, urobilinogen, protein, blood, specific gravity, ketone, bilirubin,
and glucose. At the end of the treatment period, mice were sacrificed, and blood samples were
obtained via cardiac puncture into non-heparinized and ethylenediaminetetraacetic acid (EDTA)
containing tubes for biochemical and hematological analyses.
8
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Heart, kidney, liver, spleen, and lung were isolated to assess histopathological changes. These organs
were excised, weighed (Scout PRO Ohaus, Mississauga, Ontario, Canada), examined
macroscopically, and fixed in 10 % buffered neutral formalin. Fixed organs were processed for
paraffin embedding and cuts of 5 mm thick were obtained by microtome and then processed using
an alcohol xylene series for being later stained with hematoxylin and eosin.
Hematological parameters such as red blood cell (RBC), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and white
blood cell (WBC) were analyzed using an automatic hematology analyzer (Hemat Technology,
Newton, Massachusetts, USA).
Serum biochemical parameters such as glucose, total cholesterol, triglycerides, high-density
lipoprotein cholesterol (HDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST),
albumin, total protein, and total bilirubin were analyzed using Biosystem commercial test kits with
an automated A15 spectrophotometer (Biosystems Instruments Reagents, Barcelona, Spain). The
concentrations of low-density lipoprotein cholesterol (LDL-c) were estimated using the formula by
Friedewald et al., (1972):
LDL-c (mg/dL) = [total cholesterol (TC) (mg/dL) HDL (mg/dL) - (triglycerides
(TG) (mg/dL)/5)] Eq (4)
2.10 Statistical analysis
Data were expressed as mean values ± standard error (SE). Statistical significance was
determined by one-way variance analysis (ANOVA) (p < 0.05) followed by Tukey´s test, Statistical
analysis was conducted using the Sigma Plot software version 13.0 (Systat Software, Inc., San Jose,
CA, USA).
3. Results and discussion
3.1 Yield and chemical characterization
The yield of BsLI was 21.64 %. Regarding chemical characterization results, hydroxybenzoic
acids, hydroxycinnamic acids, flavonols, flavanones, and flavones were identified and quantified.
The protocatechuic acid, salicylic acid, vanillic acid, and quinic acid were the phenolic acids with the
highest concentration; whereas, quercetin, quercetin 3-O-glucoside, and luteolin were the main
flavonol compounds detected (Table 1).
9
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Table 1. Chemical characterization of Buddleja scordioides leaves infusion (BsLI)(1 %).
Tabla 1. Caracterización química de la infusión de hojas de Buddleja scordioides (BsLI)(1 %).
Compound
Rt
(min)
[M-H]-
m/z
Transitions
Content
[ng/mg of crude
extract]
Hydroxybenzoic acids
Gallic acid
1.64
169
125, 79
8.529 0.73
Protocatechuic acid
3.13
153
109, 91
258.914 9.73
2,5-dihydroxybenzoic acid
4.21
153
109, 81
183.945 0.27
4-hydroxybenzoic acid
4.41
137
93, 65
106.790 2.60
Vanillic acid
4.85
167
152, 123
138.336 1.13
Tri-hydroxybenzaldehyde
6.21
153
83
16.584 1.33
Salicylic acid
7.70
137
93, 65
401.480 43.62
Hydroxycinnamic acids
Quinic acid
1.01
191
93, 85
210.486 24.05
Chlorogenic acid
4.32
353
191, 85
27.11 2.95
4-O-caffeoylquinic acid
4.51
353
353, 179
13.717 0.48
Caffeic acid
4.85
179
135
93.348 6.94
Coumaric acid
6.19
163
119, 98
47.224 10.48
Ferulic acid
6.54
193
178, 134
51.178 1.08
4,5-dicaffeoylquinic acid
7.14
515
353, 179
3.446 0.47
Rosmarinic acid
7.73
359
197, 161
36.189 0.02
Flavonols
Rutin
6.25
609
300, 271
69.162 1.15
Quercetin 3-O-glucoside
6.48
463
300, 271
433.894 1.48
Quercetin 3-O-ß-glucuronide
6.54
477
301, 151
164.200 9.09
Quercetin
8.41
301
179, 151
466.554 2.06
Flavanones
Neohesperidin
7.77
609
301, 164
48.328 1.00
Eriodictyol
8.42
287
151, 135
5.225 0.90
Flavones
Luteolin
8.40
285
151, 133
231.853 4.55
Apigenin
8.80
269
148, 117
13.022 1.36
9.80
283
268, 211
21.021 1.30
Values are means of duplicate determinations ± standard error.
10
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
3.2 Inhibition of digestive enzymes
3.2.1 Lipase inhibition
Results of lipase assessment are depicted in Fig. 1. The BsLI showed a lower percentage of
lipase inhibition (~44%) than orlistat (~92 %). Additionally, the IC50 values were significantly higher
as compared with the positive control (16-fold) (Table 2).
Figure 1. Lipase inhibition of Buddleja scordioides leaves infusion (BsLI). Orlistat was the positive control.
Different letters in the graph indicate significant differences in the percentage of lipase inhibition. Values are
means of duplicate determinations ± standard error. (p ˂ 0.05) by Tukey's test.
Figura 1. Inhibición de la lipasa de la infusión de hojas de Buddleja scordioides (BsLI). Orlistat fue el control
positivo. Las letras diferentes en el gráfico indican diferencias significativas en el porcentaje de inhibición de la
lipasa. Los valores son medias de determinaciones duplicadas ± error estándar. (p ˂ 0.05) mediante la prueba
de Tukey.
3.2.2 -amylase inhibition
The amylase results are shown in Fig. 2. The BsLI had a higher percentage of α-amylase
inhibition than acarbose, achieving a ~96 % while acarbose had a ~78 % inhibition. On other hand,
no differences were observed for the IC50 values between BsLI and positive control (acarbose) (Table
2).
11
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Table 2. Inhibitory digestive enzymes and antioxidant assessment of Buddleja scordioides leaves infusion (BsLI)
IC50 values.
Tabla 2. Inhibición de enzimas digestivas y evaluación antioxidante de la infusión de hojas de Buddleja
scordioides (BsLI) Valores IC50.
Figure 2. α-amylase inhibition (1) and α-glucosidase inhibition (2) of Buddleja scordioides leaves infusion (BsLI).
Acarbose was the positive control. Values are means of duplicate determinations ± standard error. a,b Different
letters indicate statistical differences between BsLI and positive control (p ˂ 0.05) by Tukey's test.
Figura 2. Inhibición de α-amilasa (1) e inhibición de α-glucosidasa (2) de la infusión de hojas de Buddleja
scordioides (BsLI). La acarbosa fue el control positivo. Los valores son medias de determinaciones duplicadas ±
error estándar. a,b Las letras distintas indican diferencias estadísticas entre BsLI y el control positivo (p ˂ 0.05)
mediante la prueba de Tukey.
Orlistat
(µg/µL)
Acarbose
(µg/µL)
Trolox
(µg/µL)
BsLI
(µg/µL)
Lipase
0.34 ± 0.01a
---
---
5.50 ± 0.01b
-amylase
---
1.69 ± 0.81a
---
1.83 ± 0.01a
-glucosidase
---
1.64 ± 0.04a
---
7.60 ± 0.10b
ABTS
---
---
1.93 ± 0.01a
1.48 ± 0.01a
DPPH
---
---
2.11 ± 0.01a
2.05 ± 0.01a
Results are expressed as inhibitory median concentration (IC50) values. Values are means of
duplicate determinations ± standard error. a-c Different letters indicate statistical differences
(p ˂ 0.05) by Tukey's test.
12
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
3.2.3 α -glucosidase inhibition
Fig. 2 shows the results of α-glucosidase inhibition. The BsLI had a lower percentage of α-
glucosidase inhibition (~19 %) than acarbose (~94 %). Regarding IC50 values, BsLI was 4-fold higher
than the positive control (Table 2).
3.4 Oral starch tolerance test (OSTT)
Variations in serum-TG onset time and area-under-time-curve (AUC) are depicted in Fig. 3.
Both groups treated with acarbose and BsLI showed significantly reduced glucose levels at 60 (above
12 %) and 120 min (above 14 %) in comparison with the control group.
Figure 3. Oral starch tolerance test (OSTT) (1) and Area-under-time-curve (AUC) (2) in rats treated with Buddleja
scordioides leaves infusion (BsLI). Acarbose was used as apositive control. Values are means of duplicate
determinations ± standard error. (*) indicates statistical differences between study groups, whereas for AUC a,b
different letters indicate statistical differences between groups (p ˂ 0.05) by Tukey's test.
Figura 3. Prueba de tolerancia oral al almidón (OSTT) Prueba oral de tolerancia al almidón (OSTT) (1) y área
bajo la curva de tiempo (AUC) (2) en ratas tratadas con infusión de hojas de Buddleja scordioides (BsLI). La
acarbosa se utilizó como control positivo. Los valores son medias de determinaciones duplicadas ± error
estándar. (*) indica diferencias estadísticas entre los grupos de estudio, mientras que para AUC a,b letras
diferentes indican diferencias estadísticas entre los grupos (p ˂ 0,05) por la prueba de Tukey.
3.5 Oral BsLI-bioactive-compounds absorption evaluation (OBAC)
Polyphenols detected in the serum of mice are shown in Fig. 4. Bioactive compounds such
as 4-hydroxybenzoic acid, naringenin, eriodictyol, luteolin, quercetin, and coumaric acid were
identified in serum mice at different times after BsLI administration. The coumaric acid (13.84 ng/µL)
and luteolin (16.01 ng/µL) exhibited the highest concentration; nevertheless, these levels declined
rapidly.
13
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Figure 4. Inhibition percentage of Buddleja scordioides leaves infusion (BsLI) on ABTS (1) and DPPH (2)
assessment. Trolox was the positive control. Values are means of duplicate determinations ± standard error. a,b
Different letters indicate statistical differences between BsLI and positive control (p ˂ 0.05) by Tukey's test.
Figura 4. Porcentaje de inhibición de la infusión de hojas de Buddleja scordioides (BsLI) en la evaluación ABTS (1)
y DPPH (2). Trolox fue el control positivo. Los valores son medias de determinaciones duplicadas ± error
estándar. a,b Las letras distintas indican diferencias estadísticas entre BsLI y el control positivo (p ˂ 0.05)
mediante la prueba de Tukey.
3.6 Antioxidant activity of BsLI in vitro.
3.6.1 ABTS and DPPH
Antioxidant evaluation of the BsLI by ABTS and DPPH assays is shown in Fig. 5. On one
hand, ABTS results, showed that the BsLI had inhibition percentage like Trolox. On other hand, BsLI
exhibited a lower inhibition percentage (~70 %) of DPPH radical compared with Trolox (~91 %).
There were no significant differences for IC50 between the treatments for both, ABTS and DPPH
assessment (Table 2).
14
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Figure 5. Means of total polyphenols of Buddleja scordioides leaves infusion (BsLI) in mice serum: (1)
hydroxybenzoic acids, (2) hydroxycinnamic acids, (3) flavones y flavonols, and (4) flavanones. Values are
expressed as mean ± standard error.
Figura 5. Medias de polifenoles totales de la infusión de hojas de Buddleja scordioides (BsLI) en suero de
ratones: (1) ácidos hidroxibenzoicos, (2) ácidos hidroxicinámicos, (3) flavonas y flavonoles, y (4) flavanonas. Los
valores se expresan como media ± error estándar.
3.7 Acute and sub-chronic toxicity evaluation
A single oral dose of infusion of BsLI (5000 mg/kg of body weight) produced no signs of
toxicity (tremors, convulsions, salivation, diarrhea, lethargy, sleepiness, or coma) or mortality after
14 days. No significant difference in body weight gain was observed. No gross pathological
abnormalities were observed in both groups. Furthermore, histological analysis of isolated organs
showed no abnormal changes (data not shown). Thus, the LD50 value was found to be greater than
5000 mg/kg.
Regarding sub-chronic toxicity evaluation, there were no significant differences between the study
groups for body weight, water, and food consumption (data not shown).
Macroscopic analysis of liver, lung, spleen, kidney, and heart exhibited no significant changes in
color and texture compared with the control group. Additionally, intervention with BsLI samples at
different doses did not affect the weight of organs.
Sub-chronic oral administration BsLI samples at different doses had no significant differences in the
urinary biochemical parameters compared with the control group (data not shown). Moreover,
treatment with BsLI showed no significant changes in serum concentrations of glucose, liver
enzymes, total bilirubin, total protein content, albumin, total cholesterol, HDL-c, LDL-c, and
triglycerides in comparison with the controls (Table 3).
Sub-chronic oral administration BsLI samples at different doses exhibited no significant changes on
hematological profile compared with the control group (Table 4).
15
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Histological analysis of heart, kidney, liver, spleen, and lung of intervention groups treated with
different doses of BsLI (250, 750 y 2500 mg/kg of body weight) revealed no abnormal changes
compared with the control group (data not shown).
Our results showed that BsLI decreases carbohydrate absorption in vivo, which could be explained
by the inhibition of digestive enzymes involved in glucose metabolism. Also, we found an
antioxidant activity in these herbal infusions.
Although the BsLI exhibited a lower percentage of lipase inhibition than orlistat, this effect could
reduce the absorption of lipids in vivo. However further studies to examine the impact of BsLI on
lipid metabolism are required.
Regarding carbohydrate digestive enzymes, BsLI showed higher inhibition of α-amylase than
acarbose. This effect could be attributed to bioactive compounds present in BsLI such as polyphenols.
It has been reported that the hydroxyl groups of these compounds interact with the enzyme active
site, allowing the formation of ligands with the catalytic residues of the binding site and,
consequently the generation of a conjugated system, resulting in the inactivation of the enzyme
(Narita and Inouye, 2009).
On other hand, BsLI had a minimal inhibitory effect on α-glucosidase. This lack of effect could be
because we employed p-nitrophenyl glucoside as substrate and α-glucosidase from a yeast,
Saccharomyces cerevisiae. This test only indicates a general glucosidase activity (Williamson, 2013);
therefore, further investigation to determine the effect of BsLI on α-glucosidase inhibition using
other substrates such as sucrose and enzyme from other sources (e.g. porcine small intestine) is
mandatory.
Our results showed that the BsLI decreases the absorption of starch similarly to acarbose. We
attribute this effect to the inhibitory activity of BsLI on α-amylase. Given that the hydrolysis of the
polysaccharide to produce limited dextrins, maltose, and maltotriose is catalyzed by α-amylase,
inhibition of both salivary and pancreatic α-amylase decreases meal-derived carbohydrate
absorption (Robyt et al., 2008).
In the present study, we detected phenolic compounds (quercetin, rutin, luteolin, and phenolic acids)
with well-established biological activity (Deng et al., 2020; Sok et al., 2021), which could be
responsible for the beneficial effects of BsLI. However, it is important to consider that the biological
action of polyphenols depends on their absorption and interaction with target tissues (Silberberg et
al., 2006). In this regard, we analyzed the absorption of bioactive compounds of BsLI in serum mice.
The main metabolites identified in BsiLI were phenolic acids and flavonoids. Additionally, the
plasma levels of these compounds suggest relatively rapid absorption, which is partly consistent
with previous studies (Liu et al., 2002).
Also, it has been reported that the bioactive compounds contained in this herbal infusion have
antioxidant effects (Moretti et al., 2012; Tian et al., 2021). In this line, the results of our study
demonstrated that BsLI exhibits antioxidant properties by scavenging free radicals (ABTS and
DPPH). It has been suggested that an ideal antidiabetic agent should have antioxidant activity (Mai
et al., 2007); thus, in addition to the hypoglycemic action, the BsLI could emerge as a therapeutic
alternative for diabetes management.
16
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
The toxicological activity of medicinal plants is an important aspect that must be assessed before
being recommended as alternative therapies (Nasri, 2013). In this context, we evaluate the acute and
chronic toxicological effects of BsLI and our results revealed no signs of toxicity, macroscopic
abnormalities, or mortality, suggesting non-toxic effects of these herbal infusions. Usually, the
consumption of infusions in Mexican communities is one cup per day at 1 % (m/v) concentration
(equivalent to 33 mg/kg of body weight). Interestingly, although we used higher doses (7.5 [250
mg/kg], 22.7 [750 mg/kg] and 75 [2500 mg/kg] times), none of these caused signs of toxicity, damage
symptoms or mortality. Additionally, all hematological and biochemical parameters remained
within the reference range for CD1 mice (Titlow, 2013) and no significant differences were observed
between the study groups. Particularly, it is noteworthy that after treatment with BsLI we found no
significant differences in transaminase levels or abnormal changes in liver tissue by histological
examination, suggesting that this natural agent does not induce hepatocellular damage. Also,
macroscopic and microscopic evaluation of the organs from mice receiving oral administration of
BsLI for 28 days at different doses (250, 750, and 2500 mg/kg) revealed normal architecture indicating
no detrimental changes or morphological disorders in the sub-chronic toxicity assessment. Hence,
the no-observed-adverse-effect level (NOAEL) may be considered for this herbal product. The BsLI
could be considered a promising and attractive strategyin the treatment of chronic diseases such as
obesity and type II diabetes; however, future clinical studies investigating the effects of these herbal
infusions are needed to confirm our findings.
Table 3. Liver function indices of CD-1 mice administrated orally with Buddleja scordioides leaves infusion (BsLI)
for 28 consecutive days.
Tabla 3. Índices de función hepática de ratones CD-1 administrados por vía oral con infusión de hojas de
Buddleja scordioides (BsLI) durante 28 días consecutivos.
Control group
250
(mg/kg)
750
(mg/kg)
2500
(mg/kg)
AST (IU/L)
193.00 ± 6.20 a
184.55 ± 11.46 a
180.78 ± 13.87 a
193.52 ± 19.53 a
ALT (IU/L)
65.47 ± 1.85 a
59.75 ± 4.17 a
49.56 ± 3.16 a
49.05 ± 5.70 a
Total Protein (g/dL)
4.99 ± 0.06 a
5.05 ± 0.06 a
5.31 ± 0.05 a
5.07 ± 0.10 a
Albumin (g/dL)
2.53 ± 0.28 a
1.61 ± 0.07 a
1.96 ± 0.07 a
1.86 ± 0.08 a
Total bilirubin
(mg/dL)
0.14 ± 0.09 a
0.12 ± 0.09 a
0.15 ± 0.35 a
0.28 ± 0.18 a
Total cholesterol
(mg/dL)
104.12 ± 1.89 a
99.14 ± 3.25 a
101.71 ± 2.87 a
98.43 ± 1.47 a
17
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
ALT: alanine aminotransferase, AST: aspartate aminotransferase, HDL-c: high density lipoprotein, and LDL-
c: low density lipoprotein. Values are expressed as mean ± standard error. Different letters indicate
statistically significant differences between groups *p 0.05 significantly different from the control were
determined by using one way ANOVA followed by Tukey’s multiple comparison tests.
Table 4. Effect on hematological parameters of oral administration with infusions of Buddleja scordioides leaves
infusion (BsLI) for 28 consecutive days.
Tabla 4. Efecto sobre los parámetros hematológicos de la administración oral con infusión de hojas de Buddleja
scordioides (BsLI) durante 28 días consecutivos.
RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean
corpuscular hemoglobin concentration, WBC: white blood cell. Values are expressed as mean ± standard
HDL-c (mg/dL)
58.16 ± 1.64 a
62.18 ± 2.23 b
59.03 ± 3.29 a
58.26 ± 1.53 a
LDL-c (mg/dL)
38.85 ± 2.31 a
24.22 ± 2.20 b
31.46 ± 1.82 a
30.73 ± 2.09 a
Triglyceride (mg/dL)
59.86 ± 3.13 a
69.86 ± 2.68 a
68.50 ± 3.83 a
77.2 ± 3.23 b
Control group
250
(mg/kg)
750
(mg/kg)
2500
(mg/kg)
RBC (×106/µL)
9.02 ± 0.19 a
8.31 ± 0.26 b
9.56 ± 0.14 a
8.67 ± 0.17 b
Hemoglobin (g/dL)
17.24 ± 0.37 b
16.51 ± 3.28 a
18.45 ± 0.34 a
16.88 ± 0.29 a
Hematocrit (%)
46.52 ± 0.98 b
44.13 ± 1.26 a
49.62 ± 0.90 a
44.77 ± 0.79 a
MCV (fL)
51.56 ± 0.07 a
53.26 ± 0.29 a
51.73 ± 0.33 a
51.671 ± 0.29 a
MCH (pg)
19.10 ± 0.04 a
19.93 ± 0.08 a
19.24 ± 0.15 a
19.50 ± 0.11 a
MCHC (g/dL)
37.03 ± 0.06 a
37.44 ± 0.13 a
37.18 ± 0.08 a
37.73 ± 0.13 a
Platelets (×103L)
1171.66 ± 4.77 a
727.85 ± 4.91 b
1047.33 ± 3.97 a
978.28 ± 4.41 a
WBC (×103/µL)
8.26 ± 2.91 a
5.68 ± 2.71 a
6.26 ± 3.03 a
5.20 ± 2.54 a
Neutrophils (%)
11.00 ± 0.51 b
9.71 ± 0.75 b
14.11 ± 0.58 a
11.86 ± 0.57 a
Eosinophils (%)
0.55 ± 0.11 a
0.57 ± 0.16 a
0.00 ± 0.00 b
0.57 ± 0.16 a
Basophils (%)
0.00 ± 0.00 c
0.14 ± 0.05 a
0.11 ± 0.04 b
0.14 ± 0.05 a
Lymphocytes (%)
87.22 ± 0.49 a
86.71 ± 0.93 a
83.56 ± 0.59 b
85.71 ± 0.43 a
Monocytes (%)
1.22 ± 0.12 c
2.86 ± 0.30 a
2.22 ± 0.90 a
1.71 ± 0.15 a
18
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
error. Different letters indicate statistically significant differences between groups *p 0.05 significantly
different from the control were determined by using one way ANOVA followed by Tukey’s multiple
comparison tests.
4. Conclusion
The study demonstrates that the infusion of Buddleja scordioides (BsLI) exerts inhibitory
effects on carbohydrate absorption in vivo by targeting digestive enzymes involved in glucose
metabolism. Moreover, BsLI exhibits antioxidant properties and contains bioactive compounds,
including phenolic acids and flavonoids. The infusion proves to be safe, with no indications of
toxicity or adverse effects on organ histology. These findings suggest that BsLI holds promise as a
potential therapeutic alternative for managing conditions such as obesity and type II diabetes.
However, further clinical studies are necessary to validate these results and explore the full potential
of BsLI as a treatment option.
Acknowledgments
This project received support from two grants: TecNM-5557.15-P and Conacyt-INFR, 2015-
253333. The author LJBZ is grateful for the graduate scholarship 1165903777 provided by the
National Council of Humanities, Sciences and Technologies (CONAHCYT). Additionally, we would
like to express our gratitude to Alejo Macías-Salas for his valuable technical support in the
histopathologic analysis.
Conflict of Interest statement
The authors declare no conflicts of interest.
5. References
Apostolidis, E., Kwon, Y. I. & Shetty, K. 2007. Inhibitory potential of herb, fruit, and fungal-enriched
cheese against key enzymes linked to type 2 diabetes and hypertension. Innov. Food Sci.
Emerg .Technol. 8(1): 46-54. https://doi.org/10.1016/j.ifset.2006.06.001
Ardeshirlarijani, E., Namazi, N., B Jalili, R., Saeedi, M., Imanparast, S., Adhami, H. R., Faramarzi,
M.A., Ayati, M.H., Mahdavi, M. & Larijani, B. 2019. Potential Anti-obesity effects of some
medicinal herb: In vitro α-amylase, α-glucosidase and lipase inhibitory activity. Int. J. Biol.
Biomed. 5(2): 2-8. http://ibbj.org/article-1-228-en.html
Awosika, T. O. & Aluko, R.E. 2019. Inhibition of the in vitro activities of α‐amylase, α‐glucosidase
and pancreatic lipase by yellow field pea (Pisum sativum L.) protein hydrolysates. Int. J. Food
Sci. 54(6): 2021-2034. https://doi.org/10.1111/ijfs.14087
19
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Brand-Williams, W., Cuvelier, M.E., & Berset, C. 1995. Use of a free radical method to evaluate
antioxidant activity. LWT - Food Science and Technology 28(1): 25-30.
https://doi.org/10.1016/S0023-6438(95)80008-5
Coruh, N., Celep, A.S. & Özgökçe, F. 2007. Antioxidant properties of Prangos ferulacea (L.) Lindl.,
Chaerophyllum macropodum Boiss. and Heracleum persicum Desf. from Apiaceae family used
as food in Eastern Anatolia and their inhibitory effects on glutathione-S-transferase. Food
Chem. 100(3): 1237-1242. https://doi.org/10.1016/j.foodchem.2005.12.006
Deng, N., Zheng, B., Li, T. & Liu, R.H. 2020. Assessment of the phenolic profiles, hypoglycemic
activity, and molecular mechanism of different highland barley (Hordeum vulgare L.)
varieties. Int. J. Mol. Sci. 21(4): 1175. https://doi.org/10.3390/ijms21041175
Estrada-Zúñiga, M.E., Gutiérrez-Rebolledo, G.A., Nieto-Trujillo, A., Bernabé-Antonio, A.& Sosa, F.C.
2019. Buddleja species distributed in Mexico against inflammatory diseases, their therapeutic
activities, secondary metabolites and biotechnology. Adv. Biol. Res. 5: 78-98.
https://stm1.bookpi.org/index.php/rabr-v5/article/view/375
Friedewald, W. T., Levy, R.I. & Fredrickson, D.S. 1972. Estimation of the concentration of low-density
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem.
18(6): 499-502. https://doi.org/10.1093/clinchem/18.6.499
Gutiérrez-Grijalva, E. P., Antunes-Ricardo, M., Acosta-Estrada, B. A., Gutiérrez-Uribe, J.A. &
Heredia, J.B. 2019. Cellular antioxidant activity and in vitro inhibition of α-glucosidase, α-
amylase and pancreatic lipase of oregano polyphenols under simulated gastrointestinal
digestion. Int. Food Res. J. 116: 676-686. https://doi.org/10.1016/j.foodres.2018.08.096
Gutiérrez-Rebolledo, G.A., Estrada-Zúñiga, M. E., Garduño-Siciliano, L., García-Gutiérrez, G. E.,
Mora, C.A.R., Calderón-Amador, J. & Cruz-Sosa, F. 2019. In vivo anti-arthritic effect and
repeated dose toxicity of standardized methanolic extracts of Buddleja cordata Kunth
(Scrophulariaceae) wild plant leaves and cell culture. J. Ethnopharmacol. 240: 111875.
https://doi.org/10.1016/j.jep.2019.111875
Hwang, S.M., Lee, Y.J., Kim, E.J., Kim, H.Y., Li, X., Choi, Y.J., Cho, N.G., Lee, H.S. & Kang, D.G. 2009.
Effect of Buddleja officinalis in Diabetic Atherosclerotic Mouse Model Using High Fat Diet.
Korea J. Herbol. 24(4): 55-62. https://doi.org/10.6116/kjh.2009.24.4.055
Irondi, E.A., Angola, S.O. & Obligor, I.E. 2018. Inhibitory effects of tropical almond leaf extract on
xanthenes oxidize, pancreatic lipase, and angiotensin 1-converting enzyme, in vitro. J. Food
Biochem. 42(4): e12481. https://doi.org/10.1111/jfbc.12481
Kopp, W. 2019. How western diet and lifestyle drive the pandemic of obesity and civilization
diseases. Diabetes Metab. Syndr. Obes.: Targets Ther. 12: 2221-2236.
https://doi.org/10.2147/DMSO.S216791
Liu, Y. & Hu, M. 2002. Absorption and metabolism of flavonoids in the caco-2 cell culture model and
a perused rat intestinal model. Drug Metabolism and Disposition 30(4): 370-377.
https://doi.org/10.1124/dmd.30.4.370
Lunagariya, N.A., Patel, N.K., Jagtap, S.C. & Bhutani, K.K. 2014. Inhibitors of pancreatic lipase: state
of the art and clinical perspectives. EXCLI J. 13: 897 -921.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464291/
20
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
Mai, T.T., Thu, N.N., Tien, P.G. & Van Chuyen, N. 2007. Alpha-glucosidase inhibitory and
antioxidant activities of Vietnamese edible plants and their relationships with polyphenol
contents. J. Nutr. Sci. Vitaminol. 53(3): 267-276. https://doi.org/10.3177/jnsv.53.267
McDougall, G.J., Kulkarni, N.N. & Stewart, D. 2009. Berry polyphenols inhibit pancreatic lipase
activity in vitro. Food Chemistry 115(1): 193-199.
https://doi.org/10.1016/j.foodchem.2008.11.093
Moretti, E., Mazzi, L., Terzuoli, G., Bonechi, C., Iacoponi, F., Martini, S., Rossi, C. & Collodel, G. 2012.
Effect of quercetin, rutin, naringenin and epicatechin on lipid peroxidation induced in
human sperm. Reprod. Toxicol. 34, 651-657. https://doi.org/10.1016/j.reprotox.2012.10.002
Narita, Y. & Inouye, K. 2009. Kinetic analysis and mechanism on the inhibition of chlorogenic acid
and its components against porcine pancreas α-amylase isozymes I and II. J. Agric. Food
Chem. 57(19): 9218-9225. https://doi.org/10.1021/jf9017383
Nasri H. & Shirzad H. 2013. Toxicity and safety of medicinal plants. J HerbMed. Plarmacol. 2(2): 21-
22.
https://www.researchgate.net/publication/285306673_Toxicity_and_safety_of_medicinal_pl
ants
National Institutes of Health (US). 2002. Office of Laboratory Animal Welfare, United States. Public
Health Service. Public Health Service policy on humane care and use of laboratory animals.
Office of Laboratory Animal Welfare, National Institutes of Health, Department of Health
and Human Services.
https://grants.nih.gov/grants/olaw/references/phspolicylabanimals.pdf
Norma Oficial Mexicana NOM-062-ZOO-1999. 1999. Especificaciones técnicas para la producción,
cuidado y uso de los animales de laboratorio.
https://www.gob.mx/cms/uploads/attachment/file/203498/NOM-062-ZOO-1999_220801.pdf
OECD. 2001. Guidelines for Acute Toxicity of Chemicals. Organization for Economic Co-operation
and Development No. 420. Published online Paris, France.
OECD. 2008. Guidelines for Repeated Dose 28-day Oral Toxicity Study in Rodents Organization for
Economic Co-operation and Development No. 407. Published online Paris, France.
Patil, P., Mandal, S., Tomar, S.K. Anand, S. 2015. Food protein-derived bioactive peptides in
management of type 2 diabetes. Eur. J. Nutr. 54, 863880. https://doi.org/10.1007/s00394-
015-0974-2
Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C. 1999. Antioxidant activity
applying an improved ABTS radical cation decolorization assay. Free Radic. Biol. Med. 26,
1231-1237. https://doi.org/10.1016/S0891-5849(98)00315-3
Reagan‐Shaw, S., Nihal, M., Ahmad, N. 2008. Dose translation from animal to human studies
revisited. FASEB J. 22, 659-661. https://doi.org/10.1096/fj.07-9574LSF
Robyt, J.F. 2008. in: Fraser-Ried, B. O., Tatsuta, K., Thiem, J., Cote´, G.L., (Eds.), Glycoscience,
Springer-Verlag, Berlin, Heidelberg, Germany; 14371472.
Rocha-Guzmán, N. E., Simental-Mendía, L. E., Barragán-Zúñiga, L. J., Ramírez-España, J. C.,
Gallegos-Infante, J. A., Lujan-Mendoza, C. I., Gamboa-Gómez, C. I. (2018). Effect of Buddleja
21
Barragán-Zúñiga et.al
TECNOCIENCIA CHIHUAHUA, Vol. XVII (2) e 1221 (2023)
scordioides K. leaves infusion on lipid peroxidation in mice with ultraviolet light-induced
oxidative stress. J. Med. Chem. 27, 2379-2385. https://doi.org/10.1007/s00044-018-2243-4
Santos-Cruz, L.F., Ávila-Acevedo, J.G., Ortega-Capitaine, D., Ojeda-Duplancher, J.C., Perdigón-
Moya, J.L., Hernández-Portilla, L.B., López-Dionicio, H., Drán-Díaz, A., Duas-Gracía, I. E.,
Castañeda-Partida, L., García-Bores, A. M., Heres-Pulido, M. E. 2012. Verbascoside is not
genotoxic in the ST and HB crosses of the Drosophila wing spot test, and its constituent,
caffeic acid, decreases the spontaneous mutation rate in the ST cross. Food Chem. Toxicol.,
50(3-4), 1082-1090. https://doi.org/10.1016/j.fct.2011.12.006
Silberberg, M., Besson, C., Manach, C., Remesy, C., Morand, C. 2006. Influence of dietary antioxidants
on polyphenol intestinal absorption and metabolism in rats. J. Agric. Food Chem. 54, 3541-
3546. https://doi.org/10.1021/jf060104e
Sok Yen, F., Shu Qin, C., Tan Shi Xuan, S., Jia Ying, P., Yi Le, H., Darmarajan, T., Gunasekaran, B.,
Salvamani, S. 2021. Hypoglycemic Effects of Plant Flavonoids: A Review. Evid. Based
Complement. Alternat Med. 2021. https://doi.org/10.1155/2021/2057333
Tamil, I.G., Dineshkumar, B., Nandhakumar, M., Senthilkumar, M., Mitra, A. 2010. In vitro study on
α-amylase inhibitory activity of an Indian medicinal plant, Phyllanthus amarus. Indian J.
Pharmacol. 42, 280. https://doi.org/10.4103/0253-7613.70107
Tian, C., Liu, X., Chang, Y., Wang, R., Lv, T., Cui, C., Liu, M. 2021. Investigation of the anti-
inflammatory and antioxidant activities of luteolin, kaempferol, apigenin and quercetin. S.
Afr. J. Bot. 137, 257-264. https://doi.org/10.1016/j.sajb.2020.10.022
Titlow WB. 2013. Characterization of Toxicological Properties of L-Lysine Polymers in CD-1 Mice. J.
Microbiol. Biotechnol. 23, 1015-1022. https://doi.org/10.4014/jmb.1302.02055
VanderJagt, T.J., Ghattas, R., VanderJagt, D.J., Crossey, M., Glew, R.H. 2002, Comparison of the total
antioxidant content of 30 widely used medicinal plants of New Mexico. Life Sci. 70, 1035-
1040. https://doi.org/10.1016/S0024-3205(01)01481-3
Villegas-Novoa, C., Moreno-Jiménez, M.R., Rocha-Guzmán, N.E. 2020. Infusión de la planta
medicinal Buddleja scordioides Kunth utilizada para tratar la inflamación intestinal.
CienciaUAT. 14, 21. https://doi.org/10.29059/cienciauat.v14i2.1287
Williamson, G. 2013. Possible effects of dietary polyphenols on sugar absorption and digestion. Mol.
Nutr. Food Res. 57, 48-57. https://doi.org/10.1002/mnfr.201200511
2023 TECNOCIENCIA CHIHUAHUA
Esta obra está bajo la Licencia Creative Commons Atribución No Comercial 4.0 Internacional.
https://creativecommons.org/licenses/by-nc/4.0/